Nurix Therapeutics (NRIX) AI Stock Analysis

• Market Cap: $1.88B
• Dividend Yield: N/A
• Average Volume (3M): 1.94M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.39
• Revenue Growth: 48.32%
• EPS Growth: -1.91%
• Country: US
• Employees: 286
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.03
• Shares Outstanding: 101,369,230
• 10 Day Avg. Volume: 2,772,582
• 30 Day Avg. Volume: 1,940,606
• PEG Ratio: -0.88
• Price to Book (P/B): 2.82
• Price to Sales (P/S): 27.21
• P/FCF Ratio: -8.16
• Enterprise Value/Market Cap: 0.41
• Enterprise Value/Revenue: 9.13
• Enterprise Value/Gross Profit: -5.61
• Enterprise Value/Ebitda: -3.04
• 1Y Price Target: $27.53
• Price Target Upside: 42.35% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 16
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 54 Neutral
• Price Target: $22.00 ▲(13.75% Upside)

Nurix Therapeutics' overall stock score is driven by its strong technical momentum and positive corporate developments. However, financial challenges and valuation concerns weigh on the score, reflecting the company's current profitability and cash flow issues.

Positive Factors

Clinical Trial Success

Positive clinical trial results for bexobrutideg indicate strong potential for future drug approval and market entry, enhancing Nurix's competitive position in the oncology sector.

Strategic Partnerships

Strategic partnerships provide a stable revenue stream and access to resources, supporting Nurix's R&D efforts and long-term growth in the biopharmaceutical industry.

Board Expertise

Adding experienced leaders to the board strengthens Nurix's strategic direction and decision-making in advancing its clinical pipeline and exploring new treatment areas.

Negative Factors

Profitability Challenges

Ongoing profitability issues and cash flow management challenges could hinder Nurix's ability to sustain operations and invest in future growth, impacting long-term viability.

Negative Cash Flow

Persistent negative cash flow indicates difficulty in funding operations internally, which may necessitate additional financing and impact financial stability.

Declining Revenue Growth

Struggles with revenue growth reflect potential market saturation or competitive pressures, posing risks to Nurix's ability to expand its market share and drive future earnings.

Nurix Therapeutics Business Overview & Revenue Model

Company Description

Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally available Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It also develops NX-0255, a CBL-B inhibitor for ex vivo use to enhance adoptive T-cell therapy; and DeTIL-0255 that is in the Phase 1 clinical trial for the treatment of gynecologic cancers, including ovarian, endometrial, and cervical cancer. The company has a strategic collaboration agreement with Gilead Sciences, Inc. for cancer and other challenging diseases patients; and Sanofi S.A. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. The company was incorporated in 2009 and is headquartered in San Francisco, California.

How the Company Makes Money

Nurix Therapeutics generates revenue primarily through a combination of partnerships, collaborations, and funding from research grants. The company often enters into strategic collaborations with larger pharmaceutical companies, which can include upfront payments, milestone payments upon reaching specific development stages, and royalties on future sales of products developed through these partnerships. Additionally, Nurix may receive funding from government grants and investments to support its research and development efforts, contributing to its overall revenue stream. The company's focus on advancing its pipeline of therapeutics also positions it for potential future revenue through the commercialization of its drug candidates.

Nurix Therapeutics Financial Statement Overview

Summary

Nurix Therapeutics demonstrates strong gross margins and low leverage, but struggles with profitability and cash flow management. The company faces challenges in achieving revenue growth and improving operational efficiency, which are critical for future financial stability.

Income Statement

Nurix Therapeutics shows a strong gross profit margin of 90.44% in TTM, indicating effective cost management. However, the company faces significant challenges with negative net profit margins and declining revenue growth, reflecting ongoing profitability issues.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.12 in TTM, suggesting conservative leverage. However, the negative return on equity highlights inefficiencies in generating returns from shareholders' investments.

Cash Flow

Nurix Therapeutics has a positive free cash flow to net income ratio, indicating some efficiency in cash generation relative to net income. However, the negative operating cash flow and free cash flow growth suggest ongoing cash management challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	83.69M	54.55M	76.99M	38.63M	29.75M	17.82M
Gross Profit	-136.30M	-167.08M	-112.16M	-145.87M	-86.68M	-48.67M
EBITDA	-251.42M	-205.01M	-148.93M	-179.72M	-115.90M	-62.80M
Net Income	-244.78M	-193.57M	-143.95M	-180.36M	-117.19M	-43.24M
Balance Sheet
Total Assets	522.47M	669.34M	355.60M	416.76M	476.77M	396.34M
Cash, Cash Equivalents and Short-Term Investments	428.83M	609.58M	287.91M	309.14M	295.72M	281.15M
Total Debt	56.49M	28.30M	30.61M	11.96M	13.04M	0.00
Total Liabilities	150.22M	142.35M	155.10M	113.06M	134.47M	106.07M
Stockholders Equity	372.25M	526.99M	200.49M	303.70M	342.30M	290.27M
Cash Flow
Free Cash Flow	-241.36M	-181.86M	-89.77M	-172.05M	-90.03M	-4.63M
Operating Cash Flow	-230.38M	-172.58M	-81.36M	-159.81M	-84.36M	-80.00K
Investing Cash Flow	6.69M	-257.71M	68.30M	27.20M	-108.25M	-254.40M
Financing Cash Flow	203.16M	485.67M	3.22M	117.19M	153.88M	339.02M

Nurix Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 19.34
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NRIX, the sentiment is Positive. The current price of 19.34 is above the 20-day moving average (MA) of 18.17, above the 50-day MA of 14.33, and above the 200-day MA of 11.73, indicating a bullish trend. The MACD of 1.28 indicates Positive momentum. The RSI at 60.17 is Neutral, neither overbought nor oversold. The STOCH value of 16.69 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NRIX.

Nurix Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ARVN	61 Neutral	$750.14M	-15.34	―	―	―	―
RLAY	59 Neutral	$1.46B	-4.92	-41.14%	―	-16.50%	33.02%
NRIX	54 Neutral	$1.88B	-6.52	-65.35%	―	48.32%	-1.91%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VIR	48 Neutral	$801.36M	-1.66	-49.06%	―	-78.55%	7.74%
TERN	45 Neutral	$4.24B	―	-29.12%	―	―	12.45%

Nurix Therapeutics Corporate Events

Nurix Therapeutics Reports Promising Data at Hematology Meeting

On December 6 and 8, 2025, Nurix Therapeutics announced new clinical data from its Phase 1a/1b study of the BTK degrader bexobrutideg (NX-5948) at the 67th American Society of Hematology Annual Meeting. The data showed promising efficacy and safety results in patients with relapsed or refractory chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and Waldenström macroglobulinemia (WM). The study highlighted an objective response rate of 83% in CLL patients and a disease control rate of 95.7%, with the 600 mg dose showing higher response rates and longer progression-free survival compared to the 200 mg dose. These findings support the advancement of the 600 mg dose into further clinical development, reinforcing bexobrutideg’s potential as a transformative treatment for B-cell malignancies.

Nurix Therapeutics Appoints Roger Dansey to Board

On November 6, 2025, Nurix Therapeutics appointed Roger Dansey, M.D., to its board of directors and as a member of the Clinical and Commercialization Committee. Dr. Dansey, with a distinguished career in oncology and drug development, is expected to enhance the board’s expertise as Nurix advances its clinical trials and explores new treatments in protein degradation for cancer and autoimmune diseases.

Nurix Therapeutics Announces $250M Stock Offering

On October 22, 2025, Nurix Therapeutics announced an underwriting agreement to offer 24,485,799 shares of common stock at $10.21 per share, expecting gross proceeds of $250 million. The net proceeds will primarily fund clinical development of drug candidates, including bexobrutideg for chronic lymphocytic leukemia, and expand research and development activities. The offering, involving both new and existing investors, is set to close on October 23, 2025, subject to customary conditions, and is part of a shelf registration filed with the SEC.

Nurix Therapeutics Initiates DAYBreak Phase 2 Trial

On October 22, 2025, Nurix Therapeutics announced the initiation of the DAYBreak clinical trial, a pivotal Phase 2 study of bexobrutideg in patients with relapsed or refractory chronic lymphocytic leukemia. The trial aims to evaluate the drug’s potential to address unmet medical needs and support a potential Accelerated Approval submission. Additionally, Nurix plans a Phase 3 confirmatory trial in 2026 to further assess bexobrutideg’s efficacy. The company also presented promising data from its Phase 1a study of NX-1607, showing clinical activity in various solid tumors, indicating potential for further development.